HealthTree Foundation

Has built many patient programs and over 8 integrated software platforms to help blood cancer patients learn more about their disease and better navigate their disease. Interviewed Dr. Berenson on phase 1 data and others.

Outcomes of Triple Class Refractory Multiple Myeloma Patients | James Berenson, MD | ASH 2023 – Video
Medical Writing Bias in Myeloma Clinical Research | James Berenson, MD | ASH 2023 – Video
Assessing Lenalidomide with Patients Progressing on JAK Inhibitors | James Berenson, MD | ASH 2023 – Video

All Press

Make an Appointment

Contact Dr. Berenson's Office

Ruxolitinib Is Under Investigation as JAK Inhibition Strategy for Multiple Myeloma

Nov 6, 2024

CancerNetwork® spoke with James R. Berenson, MD, founder, medical and scientific director, and president and chief...

Ruxolitinib Elicits Few Adverse Effects When Treating Multiple Myeloma

Nov 6, 2024

CancerNetwork® spoke with James R. Berenson, MD, president and medical director of the Berenson Cancer Center, and...

Ruxolitinib/Selinexor Combo Is Being Evaluated for Multiple Myeloma

Nov 6, 2024

Encouraging preclinical data foreground a clinical trial evaluating ruxolitinib (Jakafi) with selinexor (Xpovio) in...

HealthTree Foundation

Make an Appointment

Related Articles

Ruxolitinib Is Under Investigation as JAK Inhibition Strategy for Multiple Myeloma

Ruxolitinib Elicits Few Adverse Effects When Treating Multiple Myeloma

Ruxolitinib/Selinexor Combo Is Being Evaluated for Multiple Myeloma

Myeloma-Related Conditions

James R. Berenson, MD

Quick Links

Call Us for an Appointment